Interoperability between devices from different manufacturers can improve patient care for people with diabetes. This project recommends that the Food and Drug Administration (FDA) should make it explicit that third-party interoperability for medical devices is a qualifier for expedited medical device approval through its Breakthrough Device Designation program. By making it clear to medical device sponsors that offering a third-party interoperable system would qualify their device for the Breakthrough Device Designation, the FDA will incentivize sponsors to consider third-party interoperability – enabling patient choice and faster innovation in the medical device industry.
This project was completed as part of the 2023 Summer Nonprofit and Public Interest Fellowship, a Hub program to support public interest organizations in achieving policy impact. Project author Saira Khan-Gallo served as a representative of the nonprofit Tidepool, a nonprofit that aims to make diabetes data more accessible, actionable, and meaningful.
FDA Breakthrough Device Designation for Third-Party Interoperability
Browse Related Projects
Environment
Reducing Data Centers’ Water Consumption
By Mary-Clare Bosco, Jonathan Gilmour, and Rebecca Kilberg
Tech
Protecting Sensitive Healthcare Data
By Evîn Cheikosman
Capacity Building
Protecting Workers from Harmful AI Surveillance
by Laura Dabbish